Westin SN, Labrie M, Litton JK, Blucher A, et al. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clin Cancer Res 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
PMID: 34518313